Harmony Biosciences Holdings, Inc. (HRMY) Insider Trading Activity

NASDAQ$38.7784-0.14 (-0.36%)
Market Cap
$2.24B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
575 of 826
Rank in Industry
327 of 467

HRMY Insider Trading Activity

HRMY Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$6,285,162
14
100

Related Transactions

Dayno Jeffrey M.PRESIDENT, CEO
0
$0
1
$774,245
$-774,245
Dierks JeffreyCHIEF COMMERCIAL OFFICER
0
$0
7
$2.51M
$-2.51M
Kapadia SandipCHIEF FINANCIAL OFFICER
0
$0
6
$3M
$-3M

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Insider Activity of Harmony Biosciences Holdings, Inc.

Over the last 12 months, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $6.29M worth of Harmony Biosciences Holdings, Inc. stock.

On average, over the past 5 years, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $109.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,844 shares for transaction amount of $269,049 was made by Nielsen Jack (director) on 2020‑08‑26.

List of Insider Buy and Sell Transactions, Harmony Biosciences Holdings, Inc.

2025-12-05SaleKapadia SandipCHIEF FINANCIAL OFFICER
20,000
0.0345%
$39.54
$790,896
+1.86%
2025-11-21SaleKapadia SandipCHIEF FINANCIAL OFFICER
3,427
0.0061%
$35.00
$119,945
+10.57%
2025-08-15SaleKapadia SandipCHIEF FINANCIAL OFFICER
21,573
0.0371%
$36.50
$787,378
-11.03%
2025-04-01SaleKapadia SandipCHIEF FINANCIAL OFFICER
6,987
0.0122%
$32.54
$227,386
+3.30%
2025-03-03SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
4,869
0.0086%
$32.67
$159,090
+4.41%
2025-01-27SaleKapadia SandipCHIEF FINANCIAL OFFICER
1,775
0.0031%
$38.05
$67,547
-11.33%
2025-01-27SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
1,629
0.0029%
$38.02
$61,941
-11.33%
2025-01-24SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
13,125
0.0227%
$37.31
$489,634
-10.77%
2025-01-21SaleKapadia SandipCHIEF FINANCIAL OFFICER
25,000
0.0435%
$40.18
$1M
-15.97%
2025-01-21SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
1,123
0.0019%
$40.00
$44,920
-15.97%
2025-01-21SaleDayno Jeffrey M.PRESIDENT, CEO
19,293
0.0335%
$40.13
$774,245
-15.97%
2025-01-16SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
29,475
0.0506%
$37.41
$1.1M
-11.78%
2025-01-15SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
10,507
0.0185%
$37.01
$388,841
-7.89%
2025-01-13SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
7,180
0.0128%
$37.04
$265,946
-6.61%
2024-11-05SaleValor IV Pharma Holdings, LLC10 percent owner
600,000
0.9614%
$30.30
$18.18M
+1.84%
2024-11-05SaleMarshman Fund Trust II10 percent owner
600,000
0.9614%
$30.30
$18.18M
+1.84%
2024-11-01SaleValor IV Pharma Holdings, LLC10 percent owner
4M
6.4248%
$30.30
$121.21M
+2.93%
2024-11-01SaleMarshman Fund Trust II10 percent owner
4M
6.4248%
$30.30
$121.21M
+2.93%
2024-10-29SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
21,496
0.0369%
$40.47
$870,018
-17.99%
2024-10-01SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
400
0.0007%
$40.19
$16,077
-12.58%
Total: 118
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Dayno Jeffrey M.PRESIDENT, CEO
0
0%
$0010
Kapadia SandipCHIEF FINANCIAL OFFICER
0
0%
$006
Dierks JeffreyCHIEF COMMERCIAL OFFICER
0
0%
$0027
Valor IV Pharma Holdings, LLC10 percent owner
6618033
11.5062%
$257.57M02
Marshman Fund Trust II10 percent owner
6051120
10.5206%
$235.51M12
<0.0001%
Novo Holdings A/S10 percent owner
4409803
7.667%
$171.63M10
<0.0001%
Nielsen Jackdirector
2571024
4.47%
$100.06M530
<0.0001%
Wicki Andreasdirector
2147943
3.7344%
$83.6M023
Jacobs John CPRESIDENT, CEO
0
0%
$0010
Serafin AndrewCHIEF STRATEGY OFFICER
0
0%
$001
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$831,902,292
108
9.34%
$1.83B
$54,590,806
65
21.84%
$2.46B
$47,419,530
58
17.20%
$2.11B
$1,376,668
53
18.46%
$1.85B
$571,084,134
44
4.33%
$2.36B
$7,033,101
22
-12.19%
$2.08B
$7,549,896
18
21.49%
$2.07B
$73,814,940
15
-4.77%
$2.68B
$92,580,864
14
-1.28%
$2.54B
$50,317,062
13
-3.69%
$1.95B
$138,099,519
11
2.58%
$2.46B
$94,976,497
10
-10.72%
$1.88B
$130,038,539
8
26.82%
$2.64B
$55,713,031
8
-0.36%
$2.17B
Harmony Biosciences Holdings, Inc.
(HRMY)
$25,073,947
7
-5.99%
$2.24B
$7,605,533
5
17.10%
$2.39B
$666,380
5
-16.60%
$1.92B
$9,900,000
1
-7.19%
$2.54B
$5,000,000
1
-22.84%
$2.4B

HRMY Institutional Investors: Active Positions

Increased Positions163+58.21%5M+10.38%
Decreased Positions117-41.79%10M-18.83%
New Positions45New1MNew
Sold Out Positions29Sold Out855,833Sold Out
Total Postitions326+16.43%48M-8.45%

HRMY Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$280,570.0011.94%6.93M+189,003+2.81%2025-09-30
Vanguard Group Inc$206,487.008.79%5.1M-13,604-0.27%2025-09-30
Fmr Llc$155,841.006.63%3.85M-841,220-17.94%2025-09-30
Dimensional Fund Advisors Lp$68,526.002.92%1.69M+109,405+6.92%2025-09-30
American Century Companies Inc$67,634.002.88%1.67M+168,145+11.2%2025-09-30
State Street Corp$66,987.002.85%1.65M+24,358+1.5%2025-09-30
Lsv Asset Management$64,609.002.75%1.59M+106,391+7.15%2025-09-30
Arrowstreet Capital, Limited Partnership$52,476.002.23%1.3M+388,472+42.84%2025-09-30
Valor Management Llc$51,375.002.19%1.27M-5M-80.84%2025-09-30
Geode Capital Management, Llc$50,972.002.17%1.26M+203,915+19.34%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.